Whitehawk Therapeutics (WHWK)
Develops in-licensed antibody-drug conjugates for cancer treatment.
$4.64
Pre-market−0.08 (−1.59%)
At close$4.72(+1.84%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
−$0.27
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.67−$0.36−$0.76−$0.26−$0.34−$0.32−$0.20Pending
Estimate−$0.22−$0.46$0.49−$0.51−$0.55−$0.36−$0.30−$0.27
Surprise−204.5%+21.7%−255.1%+49.0%+38.2%+11.1%+32.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$7.2M$7.1M—————Pending
Estimate——$50.0M$25.0M$33.3M—−$350.0K—
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.27 | — | — |
| Aug 2026 | −$0.30 | −$0.20 | +32.4% |
| May 2026 | −$0.36 | −$0.32 | +11.1% |
| Mar 2026 | −$0.55 | −$0.34 | +38.2% |
| Nov 2025 | −$0.51 | −$0.26 | +49.0% |
The latest year is open to everyone — the 3 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.27 | — | — | — | — | — | — |
| Aug 6, 2026 | −$0.30 | −$0.20 | +32.4% | −$350.0K | — | — | +15.5% |
| May 7, 2026 | −$0.36 | −$0.32 | +11.1% | — | — | — | +0.8% |
| Mar 12, 2026 | −$0.55 | −$0.34 | +38.2% | $33.3M | — | — | +0.3% |
| Nov 6, 2025 | −$0.51 | −$0.26 | +49.0% | $25.0M | — | — | −1.4% |
The latest year is open to everyone — the 3 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 18, 2025 | |||||||